Pastor Peptide
← Guides Videos & Interviews

Finnricks use of Krause Analytics for Peptide Testing Is Questionable

Watch: https://www.youtube.com/watch?v=7eCw7e69QzE

Summary

The video reveals the results of a careful testing comparison of peptide vials from a single vendor, sent to multiple independent laboratories to evaluate consistency and reliability in purity and mass measurements. The creator sent four vials from one batch to different testing vendors, aiming to compare how different labs perform. Despite the initial plan to use four different labs, an error by the middleman, Finnrick, led to two vials going to the same testing lab, Krauss Analytical, which raised concerns due to inconsistent results. The gold standard lab, Janoshik, tested nine vials at different times and consistently showed purity around 99.4% and mass close to 29.8 mg, confirming the vendor’s overfill claim. Chromate, another reputable US-based testing lab, also gave results consistent with Janoshik, both in purity and mass. However, Krauss Analytical’s results were significantly lower in mass, by about 13%, which is problematic because it could lead to users unknowingly ingesting larger doses than intended, posing safety risks. Finnrick plans to investigate Krauss Analytical’s discrepancies further, and one vial is still pending testing at Janoshik to confirm consistency. The takeaway is that Janoshik and Chromate provide reliable testing results, while Krauss Analytical cannot be trusted based on this data. The video emphasizes the importance of “testing the testers” to ensure accuracy and safety in peptide dosing.

Highlights

  • 🔬 Multiple independent tests confirmed consistent purity (~99.4%) and mass (~29.8 mg) for peptide vials using Janoshik, the gold standard lab.
  • 🧪 Chromate lab results closely matched Janoshik’s, reinforcing their reliability in peptide testing.
  • ⚠️ Krauss Analytical consistently reported significantly lower mass (~25.7-26.2 mg), indicating underestimation by 13% compared to other labs.
  • 🚫 Krauss Analytical’s lower mass readings pose safety risks by potentially causing overdose due to incorrect reconstitution.
  • 🕵️ Finnrick sent vials blind to Krauss Analytical to avoid bias, yet discrepancies persisted, highlighting testing reliability issues.
  • 📊 The vendor includes barcodes linking to independent testing data for transparency about peptide mass and purity.
  • 🔍 Ongoing investigation and pending tests aim to clarify and resolve inconsistencies in testing results.

Key Insights

  • 🔬 Reliability of Testing Labs Varies Significantly: The comparison reveals that not all peptide testing labs produce consistent results. Janoshik and Chromate validate each other’s readings, while Krauss Analytical deviates substantially, especially in mass measurement. This inconsistency underscores the importance of choosing reputable labs for peptide testing to ensure product safety and efficacy. Labs that underestimate mass can mislead users about dosage.
  • 🧪 Importance of Blind Testing: Sending samples blind to testing vendors removes bias and provides a more objective assessment of their accuracy. Despite this, Krauss Analytical’s results were still inconsistent, indicating potential methodological or calibration issues rather than bias. This practice should be standard to verify testing integrity.
  • ⚠️ Underestimation of Mass Has Safety Implications: If a testing lab reports a lower mass than actual, users will reconstitute peptides expecting less material, leading to inadvertent overdosing. Overdosing peptides can cause serious side effects, especially in clinical or research contexts, highlighting why precise quantification is critical.
  • 📊 Transparency via QR Codes and Independent Testing: The vendor’s inclusion of barcodes linking to independent test results is a valuable transparency measure. It allows consumers to access verified data about the peptide’s purity and mass, helping build trust and enabling informed decisions. This practice could become an industry standard for quality assurance.
  • 🔍 Need for Cross-Lab Verification: The video demonstrates the utility of cross-verifying peptide batches with multiple labs to detect discrepancies. Single-lab testing may not reveal hidden inaccuracies, so multi-lab comparisons can safeguard against erroneous data and ensure consistency.
  • 🕵️ Role of Middlemen in Sample Handling Can Affect Outcomes: The error by Finnrick in sending two vials to the same lab instead of four different labs reflects operational challenges in sample management that can affect testing scope and confidence. Careful logistics are essential in comparative studies to avoid skewed results.
  • 📈 Ongoing Investigations Are Crucial for Quality Control: Finnrick’s plan to engage Krauss Analytical and conduct further testing highlights the necessity of continuous quality control and accountability among testing labs. Such scrutiny helps maintain standards and protects end-users from unreliable data.

This comprehensive analysis of peptide testing results not only identifies reliable and unreliable labs but also stresses the critical importance of accuracy in dosing for safety and efficacy. It advocates for transparency, standardization, and rigorous verification in peptide testing protocols.